Health and Research in 2019: Five Trends to Watch | Deloitte US has been saved
Limited functionality available
By Margaret Anderson, managing director, Deloitte Consulting LLP
There is something about a new year that gives us a clearer vantage point on the trends that might lie ahead. A new year might be an artificial demarcation point, but I use it to reflect on where the health care and innovation market is now, and where it could be headed.
The exponential promise that exists in the life sciences and health care sectors is unprecedented. It used to sound trite when industry leaders would expound on this golden era of science, but now it feels like we are on firm ground. The impact of tools and techniques—such as nanotechnology, artificial intelligence (AI), and user-centered design—are being interrogated to advance innovation in health. Novel approaches are now met with less skepticism than in the past, and there appears to be an understanding that a novel concept can survive and re-enter the market even if the startup that came up with the idea fails.
Deloitte recently launched some powerful perspectives on the overall Future of Health where our thought leaders imagine what the health care, life sciences, and research sectors will look like in 2040. But how about the near term? What are some trends to watch in 2019?
I see five key trends to watch. We’ve been discussing and witnessing some of these trends for years, while others have cropped up and matured more quickly. Some trends are positive and others are not. Some are clear while others are still murky.
From systems level issues to real diseases impacting people today, we have much to do to advance solutions for people across our nation and indeed the world. We have 11 months left in 2019, and I will be watching these trends closely.
Margaret is a managing director engaging across the federal health, nonprofit, and life sciences sectors where she is focused on advancing treatments and interventions for patients, as well as helping to improve the outcomes and efficiency of research and delivery systems. Prior to Deloitte, Margaret advocated for cross-sector collaboration, cultivated a culture of innovation, and engaged patients as partners while serving as executive director of FasterCures, a Washington DC-based center of the Milken Institute. She has worked on biomedical and public health policy serving previously at the Academy for Educational Development, as program director at the Society for Women's Health Research, and as a health science analyst at the American Public Health Association. Margaret has served on national boards and committees including the National Institutes of Health (NIH), National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board, and National Health Council. She currently serves on the boards of ACT for the NIH, Asthma & Allergy Foundation, and Melanoma Research Alliance. She holds a bachelor's degree from the University of Maryland and a master's degree in science, technology & public policy from George Washington University.